Kristof Roox
Overview
Pharmaceutical and life sciences companies often have to deal with complex patent litigation. They require help from someone with a pragmatic, creative approach, and this is Kristof Roox’s particular strength. Clients reach out to Kristof for his tenacity in the courtroom as well as his to-the-point counseling on every aspect of intellectual property law.
Career & Education
- Free University of Brussels (Vrije Universiteit Brussel), J.D., cum laude, licentiate degree law, 1994
- University of London (Queen Mary and Westfield College), LL.M., intellectual property law, 1996
- Heilig-Hartcollege, Maasmechelen, 1989
- Belgium
- Intellectual Property Council, section Industrial Propert, Belgian Government, FPS Economy
- Editorial Board, IRDI
- Board of Governors, University of Brussels Law Alumni
- Dutch
- English
- French
- German
Kristof Roox is regarded by one client as ‘the number one in Brussels.’
— Chambers Europe, 2020
Kristof's Insights
Client Alert | 4 min read | 06.26.24
Preparing for the U.S. BIOSECURE Act
Momentum is building for the US BIOSECURE Act, and it is becoming more and more likely that it will soon become law. It may significantly impact pharmaceutical and biotechnology companies and supply chains, particularly if they or their customers do business with the U.S. Federal Government. It is therefore important to prepare now to avoid potentially serious adverse effects.
Press Coverage | 06.20.24
Firm News | 2 min read | 06.06.24
Representative Matters
- Regularly represents several major international pharmaceutical companies in patent infringement and invalidity litigation.
- Represents several clients in parallel import cases.
- Represented a client in a dispute regarding a new type of shock absorber for cars.
- Represents a major Belgian cable network provider in one of the most important copyright cases in Belgium regarding “direct injection,” “simulcasting” and “all rights included” contracts.
- Represents an association of music festivals in a major dispute concerning copyright royalties and abuse of dominance.
- Represented the Belgian government in high-profile litigation concerning the alleged non-respect of several court orders.
- Represents software manufacturers in licensing disputes.
- Represents a client in a white collar crime / public procurement matter.
Kristof's Insights
Client Alert | 4 min read | 06.26.24
Preparing for the U.S. BIOSECURE Act
Momentum is building for the US BIOSECURE Act, and it is becoming more and more likely that it will soon become law. It may significantly impact pharmaceutical and biotechnology companies and supply chains, particularly if they or their customers do business with the U.S. Federal Government. It is therefore important to prepare now to avoid potentially serious adverse effects.
Press Coverage | 06.20.24
Firm News | 2 min read | 06.06.24
Recognition
- IAM 1000: Gold – Firms: Litigation and Transactions, 2024
- Chambers Europe: Belgium, Intellectual Property, 2006–2024
- Chambers Europe: Belgium, Life Sciences: Domestic, 2006–2020
Kristof's Insights
Client Alert | 4 min read | 06.26.24
Preparing for the U.S. BIOSECURE Act
Momentum is building for the US BIOSECURE Act, and it is becoming more and more likely that it will soon become law. It may significantly impact pharmaceutical and biotechnology companies and supply chains, particularly if they or their customers do business with the U.S. Federal Government. It is therefore important to prepare now to avoid potentially serious adverse effects.
Press Coverage | 06.20.24
Firm News | 2 min read | 06.06.24
Practices
- Intellectual Property — Brussels Practice
- Dispute Resolution — Brussels Practice/IP
- Life Sciences — Brussels Practice
- Trademarks and Designs — Brussels Practice
- Copyright — Brussels Practice
- Copyright Counseling and Litigation
- Patents — Brussels Practice
- European Patents and Unified Patent Court — Brussels Practice
- Brussels Practice
- Technology, Media, and Telecommunications — Brussels Practice
- Health Care
- Financial Services
Industries
Kristof's Insights
Client Alert | 4 min read | 06.26.24
Preparing for the U.S. BIOSECURE Act
Momentum is building for the US BIOSECURE Act, and it is becoming more and more likely that it will soon become law. It may significantly impact pharmaceutical and biotechnology companies and supply chains, particularly if they or their customers do business with the U.S. Federal Government. It is therefore important to prepare now to avoid potentially serious adverse effects.
Press Coverage | 06.20.24
Firm News | 2 min read | 06.06.24